SpyGlass Pharma Inc. has developed an intraocular lens (IOL) capable of continuously delivering drugs to eyes for up to three ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Various types of topical therapies are effective for the treatment of periorbital dyschromia, including caffeine, growth factors, and more.

ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ ...

Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this ...

A drug-eluting contact lens that uses 3D printing technology can improve IOP and treatment compliance for patients with glaucoma.

Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Oculis Holding (OCS – Research Report) on November 7 and set a price ...

With Green Bay taking the week off, here's what stands out in five defining areas — offense, defense, special teams, ...

Treatment availability and patient outcomes are critical issues for the pharmaceutical industry, particularly in eye care.

You may have seen advertisements claiming to eliminate the need for eyeglasses through vision therapy or vision training – ...

Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing ...

Injuries gave him the opportunity, but practice and film study helped tight end Zach Ortwerth carve out a role early on in ...